Interventional × Kidney Neoplasms × 90 days × Clear all
NCT06673329 2026-05-13

Brodalumab in the Treatment of Immune-Related Adverse Events

Columbia University

Phase 1 Recruiting
11 enrolled
NCT06239194 2026-05-06

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

ModeX Therapeutics, An OPKO Health Company

Phase 1/2 Recruiting
285 enrolled